Development of antimalaria immunity in mice lacking IFN-gamma receptor.
IFN-gamma receptor deficient (IFN-gamma R-/-) mice, immunized with different developmental stages of malaria parasites, were used to define the mechanisms of protection against the various stages of this infection. IFN-gamma R-/- mice failed to develop protective immunity against Plasmodium yoelii sporozoites or liver stages, upon immunization with a single dose of irradiated sporozoites, whereas in immunized wild-type mice, parasite development was strongly inhibited. Immunized wild-type mice expressed high levels of inducible nitric oxide synthase (iNOS) mRNA in their liver, upon challenge with viable sporozoites, whereas only background levels of iNOS were detected in immunized IFN-gamma R-/- mice. In contrast, after immunization with multiple doses of irradiated sporozoites, both IFN-gamma R-/- and wild-type mice mounted an immune response, which strongly inhibited the development of liver stage parasites. In both types of mice, protection occurred in the absence of appreciable expression of liver iNOS mRNA. As for the course of the erythrocytic phase of infection by nonlethal malaria species, P. yoelii yoelii and P. chabaudi adami, we observed only a moderately prolonged parasitemia in IFN-gamma R-/- mice compared with wild-type mice, indicating that IFN-gamma may only play a modest role in immunity against erythrocytic stages. These results indicate that IFN-gamma is the main mediator of the protective mechanism that develops first upon immunization with sporozoites. However, the nature of the anti-parasite mechanism(s) changes in the course of immunization, so that multiple immunizing doses elicit additional protective mechanisms, which are independent of IFN-gamma and its receptor.
Tsuji
M
M
Department of Medical and Molecular Parasitology, New York University School of Medicine, NY 10010, USA.
Miyahira
Y
Y
Nussenzweig
R S
RS
Aguet
M
M
Reichel
M
M
Zavala
F
F
D000594:Amino Acid Oxidoreductases / Q000096:biosynthesis; D000818:Animals; D005455:Fluorescent Antibody Technique; D008288:Malaria / Q000276:immunology*; D051379:Mice; D008817:Mice, Mutant Strains; D009154:Mutation / Q000235:genetics; D019001:Nitric Oxide Synthase; D016788:Plasmodium chabaudi / Q000276:immunology*; D010967:Plasmodium yoelii / Q000276:immunology*; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000096:biosynthesis; D016053:RNA, Protozoan / Q000032:analysis; D012335:RNA, Ribosomal / Q000032:analysis; D017471:Receptors, Interferon / Q000235:genetics* / Q000276:immunology*; D000096743:Interferon gamma Receptor
D000594:Amino Acid Oxidoreductases; D019001:Nitric Oxide Synthase; D012333:RNA, Messenger; D016053:RNA, Protozoan; D012335:RNA, Ribosomal; D017471:Receptors, Interferon; D000096743:Interferon gamma Receptor